Viral sequence analysis from HIV-infected mothers and infants: Molecular evolution, diversity, and risk factors for mother-to-child transmission

Clinics in Perinatology

Volumn 37, Issue 4, 2010, Pages 739-750

  Bulterys, Philip L ^a,b   Dalai, Sudeb C ^c,d   Katzenstein, David A ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diversity; HIV; Molecular evolution; Mother to child transmission; Risk factor; Sequence

Indexed keywords

ALVAC; ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

BREAST FEEDING; DISEASE COURSE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFANT; LENTIVIRUS INFECTION; MICROBIAL ACTIVITY; MIXED INFECTION; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; SINGLE DRUG DOSE; SUPERINFECTION; VACCINE PRODUCTION; VERTICAL TRANSMISSION; VIRION; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CANCER VACCINES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECOMBINATION, GENETIC; RISK FACTORS;

EID: 78349285109     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.08.003     Document Type: Review

References (110)

1. Newell M.L., Coovadia H., Cortina-Borja M., et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004, 364:1236-1243.
2. Mofenson L.M. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2010, 50:130-148.
3. Bulterys M., Wilfert C.M. HAART during pregnancy and during breast feeding among HIV-infected women in the developing world: has the time come?. AIDS 2009, 23:2473-2477.
4. Garcia P.M., Kalish L.A., Pitt J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402.
5. Mofenson L.M., Lambert J.S., Stiehm E.R., et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999, 341:385-393.
6. Koulinska I.N., Villamor E., Msamanga G., et al. Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes. Virus Res 2006, 120:191-198.
7. Bulterys M., Landesman S., Burns D., et al. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:76-82.
8. Kourtis A.P., Bulterys M., Nesheim S., et al. Understanding the timing of HIV transmission from mother to infant. JAMA 2001, 285:709-712.
9. Kourtis A.P., Lee F.K., Jamieson D.J., et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006, 6:726-732.
10. Goedert J.J., Duliege A.M., Amos C.I., et al. High risk of HIV-1 infection for first-born twins. The International Registry of HIV-Exposed Twins. Lancet 1991, 338:1471-1475.
11. Biggar R.J., Cassol S., Kumwenda N., et al. The risk of human immunodeficiency virus-1 infection in twin pairs born to infected mothers in Africa. J Infect Dis 2003, 188:850-855.
12. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
13. Guevara H., Casseb J., Zijenah L.S., et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr 2002, 29:435-440.
14. Ioannidis J., Abrams E., Ammann A., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001, 183:539-545.
15. Leroy V., Karon J.M., Alioum A., et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002, 16:631-641.
16. Delwart E., Magierowska M., Royz M., et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 2002, 16:189-195.
17. Perelson A.S., Neumann A., Markowitz M., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 1996, 271:1582-1586.
18. Temin H.M. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci U S A 1993, 90:6900-6903.
19. Ross H.A., Rodrigo A.G. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 2002, 76:11715-11720.
20. Williamson S. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol 2003, 20:1318-1325.
21. Bonhoeffer S., Holmes E.C., Nowak M.A. Causes of HIV diversity. Nature 1995, 376:125.
22. Rambaut A., Posada D., Crandall K.A., et al. The causes and consequences of HIV evolution. Nat Rev Genet 2004, 5:52-61.
23. Zhu T., Mo H., Wang N., et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179-1181.
24. Dickover R.E., Garratty E.M., Plaeger S., et al. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001, 75:2194-2203.
25. Wolinsky S.M., Wike C.M., Korber B.T., et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
26. Ahmad N., Baroudy B.M., Baker R.C., et al. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995, 69:1001-1012.
27. Renjifo B., Chung M., Gilbert P., et al. In-utero transmission of quasispecies among human immunodeficiency virus type 1 genotypes. Virology 2003, 307:278-282.
28. Blish C.A., Blay W.M., Haigwood N.L., et al. Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res 2007, 5:578-587.
29. Kampinga G.A., Simonon A., Van de Perre P., et al. Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. Virology 1997, 227:63-76.
30. Kliks S., Contag C.H., Corliss H., et al. Genetic analysis of viral variants selected in transmission of human immunodeficiency viruses to newborns. AIDS Res Hum Retroviruses 2000, 16:1223-1233.
31. Verhofstede C., Demecheleer E., De Cabooter N., et al. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 2003, 77:3050-3057.
32. Wu X., Parast A.B., Richardson B.A., et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006, 80:835-844.
33. Kuhn L., Abrams E., Palumbo P., et al. Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression. AIDS 2004, 18:1281-1289.
34. Ceballos A., Andreani G., Ripamonti C., et al. Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding. J Gen Virol 2008, 89:2773-2782.
35. Zhuang J., Jetzt A.E., Sun G., et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol 2002, 76:11273-11282.
36. Jung A., Maier R., Vartanian J.P., et al. Multiply infected spleen cells in HIV patients. Nature 2002, 418:144.
37. Jost S., Bernard M.C., Kaiser L., et al. A patient with HIV-1 superinfection. N Engl J Med 2002, 347:731-736.
38. Koelsch K.K., Smith D.M., Little S.J., et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003, 17:11-16.
39. Crandall K.A., Templeton A.R. The evolution of HIV. Baltimore (MD) 1999, The Johns Hopkins University Press, p. 153-76.
40. McVean G., Awadalla P., Fearnhead P. A coalescent-based method for detecting and estimating recombination from gene sequences. Genetics 2002, 160:1231-1241.
41. Robertson D.L., Sharp P.M., McCutchan F.E., et al. Recombination in HIV-1. Nature 1995, 374:124-126.
42. Pandrea I., Robertson D.L., Onanga R., et al. Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. AIDS Res Hum Retroviruses 2002, 18:1103-1116.
43. Essex M., M'Boup S. Regional variation in the African epidemics. AIDS in Africa 2002, Kluwer Academic/Plenum Publishers, New York. 2nd edition.
44. Liu S.L., Mittler J.E., Nickle D.C., et al. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol 2002, 76:10674-10684.
45. Nájera R., Delgado E., Pérez-Alvarez L., et al. Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002, 16:3-16.
46. Kellam P., Larder B.A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 1995, 69:669-674.
47. Morris A., Marsden M., Halcrow K., et al. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J Virol 1999, 73:8720-8731.
48. Koulinska I.N., Villamor E., Chaplin B., et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006, 41:93-99.
49. Quan Y., Liang C., Brenner B., et al. Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants. J Infect Dis 2009, 9:1479-1483.
50. Li Y., Kappes J.C., Conway J.A., et al. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 1991, 65:3973-3985.
51. Odaibo G.N., Olaleye D.O., Heyndrickx L., et al. Mother-to-child transmission of different HIV-1 subtypes among ARV naïve infected pregnant women in Nigeria. Rev Inst Med Trop Sao Paulo 2006, 48:77-80.
52. Pádua E., Parreira R., Tendeiro R., et al. Potential impact of viral load and genetic makeup of HIV type 1 on mother-to-child transmission: characterization of env-C2V3C3 and nef sequences. AIDS Res Hum Retroviruses 2009, 25:1171-1177.
53. Bjorndal A., Sonnerborg A., Tscherning C., et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS 1999, 15:647-653.
54. Hu D.J., Vanichseni S., Mastro T.D., et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001, 15:683-691.
55. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., et al. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol 2000, 74:3740-3751.
56. Kaleebu P., French N., Mahe C., et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002, 185:1244-1250.
57. Kanki P.J., Hamel D.J., Sankale J.L., et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999, 179:68-73.
58. Neilson J.R., John G.C., Carr J.K., et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999, 73:4393-4403.
59. Tscherning C., Alaeus A., Fredriksson R., et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998, 241:181-188.
60. Blackard J.T., Renjifo B., Chaplin B., et al. Diversity of the HIV-1 long terminal repeat following mother-to-child transmission. Virology 2000, 274:402-411.
61. Renjifo B., Fawzi W., Mwakagile D., et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol 2001, 4:16-25.
62. Renjifo B., Gilbert P., Chaplin B., et al. Preferential in utero transmission of HIV-1 subtype C compared to subtype A or D. AIDS 2004, 18:1629-1636.
63. Yang C., Li M., Newman R.D., et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS 2003, 11:1667-1674.
64. Murray M.C., Embree J.E., Ramdahin S.G., et al. Effect of human immunodeficiency virus (HIV) type 1 viral genotype on mother-to-child transmission of HIV-1. J Infect Dis 2000, 181:746-749.
65. Tapia N., Franco S., Puig-Basagoiti F., et al. Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission. J Gen Virol 2003, 84:607-613.
66. Dalai S.C., de Oliveira T., Gordon W., et al. Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS 2009, 23:2523-2532.
67. Worobey M., Gemmel M., Teuwen D.E., et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664.
68. Salemi M., de Oliveira T., Ciccozzi M., et al. High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania. PLoS One 2008, 3. e1390.
69. Poss M., Martin H.L., Kreiss JK, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 1995, 69:8118-8122.
70. Poss M., Rodrigo A.G., Gosink J.J., et al. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol 1998, 72:8240-8251.
71. Kovacs A., Wasserman S.S., Burns D., et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001, 358:1593-1601.
72. Wright T.C., Subbarao S., Ellerbrock T.V., et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001, 184:279-285.
73. Ellerbrock T.V., Lennox J.L., Clancy K.A., et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001, 184:28-36.
74. Kemal K.S., Foley B., Burger H., et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003, 100:12972-12977.
75. De Pasquale M.P., Leigh Brown A.J., Uvin S.C., et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 34:37-44.
76. Adal M., Ayele W., Wolday D., et al. Evidence of genetic variability of human immunodeficiency virus type 1 in plasma and cervicovaginal lavage in ethiopian women seeking care for sexually transmitted infections. AIDS Res Hum Retroviruses 2005, 21:649-653.
77. Tirado G., Jove G., Reyes E., et al. Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART. Virology 2005, 334:299-305.
78. Philpott S., Burger H., Tsoukas C., et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol 2005, 79:353-363.
79. Sullivan S.T., Mandava U., Evans-Strickfaden T., et al. Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status. J Virol 2005, 79:9799-9809.
80. Andreoletti L., Skrabal K., Perrin V., et al. Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral-treatment-naive clade a human immunodeficiency virus type 1-infected women. J Clin Microbiol 2007, 45:1838-1842.
81. Kemal K.S., Burger H., Mayers D., et al. HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007, 195:535-545.
82. Semrau K., Ghosh M., Kankasa C., et al. Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding. J Acquir Immune Defic Syndr 2008, 47:320-328.
83. Bull M.E., Learn G.H., McElhone S., et al. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol 2009, 83:6020-6028.
84. Dyer J.R., Gilliam B.L., Eron J.J., et al. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1996, 60:161-170.
85. Si-Mohamed A., Kazatchkine M.D., Heard I., et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000, 182:112-122.
86. Min S.S., Corbett A.H., Rezk N., et al. Protease Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Concentrations in the Genital Tract of HIV-1-Infected Women. J Acquir Immune Defic Syndr 2004, 37:1577-1580.
87. Fowler M.G., Lampe M.A., Jamieson D.J., et al. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 2007, 197:3-9.
88. Kuhn L., Aldrovandi G.M., Sinkala M., et al. Effects of early, abrupt weaning for HIV-free survival of children in zambia. N Engl J Med 2008, 359:1859.
89. Becquart P., Chomont N., Roques P., et al. Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology 2002, 300:109-117.
90. Becquart P., Courgnaud V., Willumsen J., et al. Diversity of HIV-1 RNA and DNA in breast milk from HIV-1-infected mothers. Virology 2007, 363:256-260.
91. Henderson G.J., Hoffman N.G., Ping L.H., et al. HIV-1 populations in blood and breast milk are similar. Virology 2004, 330:295-303.
92. Andreotti M., Galluzzo C.M., Guidotti G., et al. Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique. AIDS Res Hum Retroviruses 2009, 25:707-711.
93. Sabbaj S., Edwards B.H., Ghosh M.K., et al. Human immunodeficiency virus-specific CD8+ T cells in human breast milk. J Virol 2002, 76:7365-7373.
94. Sabbaj S., Ghosh M.K., Edwards B.H., et al. Breast milk-derived antigen-specific CD8+ T cells: an extralymphoid effector memory cell population in humans. J Immunol 2005, 174:2951-2956.
95. Nickle D.C., Jensen M.A., Shriner D., et al. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol 2003, 77:5540-5546.
96. Becquart P., Hakim H., Benoit G., et al. Compartmentalization of the IgG immune response to HIV-1 in breast milk. AIDS 1999, 13:1323-1331.
97. Heath L., Conway S., Jones L., et al. Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmission. PLoS One 2010, 5. e10213.
98. Becquet R., Ekouevi D., Arrive E., et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009, 49:1936-1945.
99. Dabis F., Msellati P., Meda N., et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999, 353:786-792.
100. Dabis F., Bequet L., Ekouevi D.K., et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum transmission of HIV. The ANRS 1201/1202 Ditrame Plus study, Abidjan, Cote d'Ivoire. AIDS 2005, 19:309-318.
101. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
102. Lallemant M., Jourdain G., Le Coeur S., et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004, 351:217-228.
103. Petra study team Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002, 359:1178-1186.
104. Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999, 353:773-780.
105. Wiktor S.Z., Ekpini E., Karon J.M., et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999, 353:781-785.
106. Arrive E., Newell M.L., Ekouevi D.K., et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007, 36:1009-1021.
107. Luzuriaga K., Dabis F., Excler J.L., et al. Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet 2006, 368:511-521.
108. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009, 361:2209-2220.
109. Walker L., Phogat S., Chan-Hui P., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
110. Hansen S., Vieville C., Whizin N., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.